Castle Biosciences Castle Bio Adds New Outcome Data for Melanoma Assay, Shares Early Info on Skin Disease Test Premium The firm is hoping that growing real-world evidence for DecisionDx-Melanoma will support better clinical recognition as it continues to expand its menu. Castle Biosciences Q1 Revenues Grow 18 Percent The Friendswood, Texas-based molecular diagnostics company reported revenues of $26.9 million in Q1 2022, up from $22.8 million a year ago. Omics Tools and MDx Stocks Down Across the Board in April, Following Broader Market The GenomeWeb Top 40 was down 12 percent in April, while the Dow Jones, Nasdaq, and Nasdaq Biotech Index were down 5, 13, and 10 percent, respectively. Castle Biosciences, VHA Expand Supply Contract to Cover Full Skin Cancer Test Portfolio The new contract with the Veterans Health Administration makes all five of the company's skin cancer assays available for veterans, active-duty military, and family members. In Brief This Week: Natera, Caris Life Sciences, Fulgent Genetics, Castle Biosciences, More News items for the week of April 25, 2022 Apr 5, 2022 Castle Biosciences to Acquire AltheaDx for $65M Apr 1, 2022 In Brief This Week: Biocept, SeqLL, Castle Biosciences, VolitionRx, More Mar 2, 2022 Castle Bio Adds Data for DecisionDx Melanoma Assay, Eyes Squamous Cell Carcinoma Reimbursement Premium Feb 28, 2022 Castle Biosciences Q4 Revenues Grow 45 Percent Feb 3, 2022 Castle Biosciences Working With NCI on SEER Registry Study of DecisionDx-Melanoma Feb 1, 2022 Stocks of Genomics Tools and MDx Firms Hit Hard in January Sell-off Jan 10, 2022 CareDx, Castle Bio, Lucira Health, Others Announce Preliminary Q4, FY21 Earnings Results Dec 1, 2021 GenomeWeb Index Falls 6 Percent in November as Emergence of Omicron Spooks Markets Nov 8, 2021 Castle Biosciences Q3 Revenues Rise 54 Percent Oct 27, 2021 Castle Biosciences Buy of Cernostics Aligns With Goal to Diversify Portfolio Premium Oct 19, 2021 Castle Biosciences Acquires Cernostics for up to $80M Sep 16, 2021 Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test Aug 24, 2021 Castle Biosciences Awarded VA Supply Contract for Melanoma Test Aug 9, 2021 Castle Biosciences Q2 Revenues Rise 79 Percent Jul 16, 2021 People in the News: New Appointments at Castle Biosciences, Oxford Nanopore, PGDx, More Jun 9, 2021 Castle Biosciences Receives NYS DOH Approval for Skin Cancer Diagnostic May 14, 2021 People in the News: New Appointments at Berkeley Lights, Castle Bio, IsoPlexis, More May 11, 2021 Castle Biosciences to Expand Range of Dermatology Diagnostics Beyond Cancer Premium May 10, 2021 Castle Biosciences Q1 Revenues Up 31 Percent Apr 27, 2021 Castle Biosciences Acquires Myriad Genetics' MyPath Melanoma Test, Lab for $32.5M Load More Breaking News People in the News at Pacific Biosciences, Metabolon, NeoGenomics, More New Products Posted to GenomeWeb: Tethis, Invitae, PerkinElmer, More In Brief This Week: Thermo Fisher Scientific, Bruker, Quantum-Si, BioMérieux, More Luminex Obtains CE Marking for MDx Panel to Detect Flu A/B, RSV, COVID-19 Palmetto Finalizes Positive LCD for Prostate Cancer Risk Tests Gene Expression, Histology Reveal Clues for Targeted Rheumatoid Arthritis Treatment The Scan Call for a Different Tack Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News. Wastewater Warning The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge. Can't Get in the Program Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports. Science Paper on Spatial-Controlled Genome Editing In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.